A new treatment for menopause symptoms has just been approved by the U.S. Food and Drug Administration, offering hope to millions of women who struggle with hot flashes, night sweats, and sleep problems.
The drug, called elinzanetant, was tested at UVA Health and many other medical centers across the United States and around the world.
The results showed that the drug can greatly reduce both how often hot flashes happen and how severe they feel. It also helps women sleep better and improves their overall quality of life.
Elinzanetant is noteworthy because it is not a hormone-based treatment. Many women cannot or do not want to take hormone therapy due to side effects, personal preferences, or medical risks. Hormone therapy usually involves estrogen, which is effective for treating menopause symptoms but is not suitable for everyone.
Some women may experience breast tenderness, bloating, headaches, or spotting from hormone therapy. Others face more serious risks, such as increased chances of blood clots, strokes, or certain cancers.
Women with a history of blood clots or estrogen-sensitive cancers are often advised not to take hormone therapy at all. Because of these concerns, a safe and effective nonhormonal option has been needed for a long time.
Menopause symptoms such as hot flashes happen because estrogen levels drop during midlife. These sudden waves of heat can continue for years and can seriously affect daily life. Many women struggle with sleeping through the night, concentrating at work, or even managing simple tasks at home.
According to Dr. JoAnn V. Pinkerton, director of midlife health at UVA Health, more than one in three women experiences symptoms so disruptive that they last for more than ten years.
She explains that many women continue to suffer silently without proper support or treatment options. With the approval of elinzanetant, there is finally a new choice for women who need relief but cannot take hormones.
To test the drug, scientists ran double-blinded clinical trials across the United States, Europe, and Israel. This means neither the researchers nor the participants knew who was receiving the real drug and who was getting a placebo.
The participants were postmenopausal women between 40 and 65 years old who had moderate to severe hot flashes. Half of the group took a daily 120 mg dose of elinzanetant for 26 weeks, while the other half took a placebo for 12 weeks and then switched to the real drug for the remaining 14 weeks.
The results were impressive. Women taking elinzanetant felt improvements quickly, with fewer and milder hot flashes appearing within the first week. By week 12, women reported better sleep and an improved sense of well-being.
Many said they felt more rested, less irritable, and more capable of enjoying everyday activities again. This shows how meaningful the effects can be for women who have struggled for years.
Researchers also carefully checked for side effects. The most common ones were mild headache and mild tiredness. Importantly, the study found no serious side effects. This safety profile helped the FDA decide to approve the drug. The findings suggest that elinzanetant can be used safely by a wide range of women, including those who cannot take estrogen.
Dr. Pinkerton says she is thrilled that women now have access to an effective FDA-approved nonhormonal therapy. She emphasizes the importance of listening to women and taking their symptoms seriously. Understanding what they are dealing with helps doctors provide treatments that truly support their needs and improve their daily lives.
After reviewing the study results, it is clear that elinzanetant fills a major gap in menopause care. Until now, women who could not take hormone therapy had very limited options, often leaving them to tolerate hot flashes, sleepless nights, and mood changes on their own.
The trials showed that the drug provides fast relief, lasting improvements, and minimal side effects. While more long-term studies may help understand how the drug works over many years, the current evidence strongly supports its use. This new treatment offers a hopeful and practical solution for women seeking a safer alternative to hormone therapy.
If you care about heart health, please read studies that apple juice could benefit your heart health, and Yogurt may help lower the death risks in heart disease.
For more information about health, please see recent studies that Vitamin D deficiency can increase heart disease risk, and results showing Zinc and vitamin B6 linked to lower death risk in heart disease.
Copyright © 2025 Knowridge Science Report. All rights reserved.
